NLRP3 and ischemic stroke: The positive result of the CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) highlights the importance of IL-1β in the risk of recurrent cardiovascular events.19 Moreover, NLRP3 has been demonstrated to contribute to the vascular inflammatory response driving atherosclerosis,20 suggesting that NLRP3 could contribute to an increased risk of ischemic stroke.